Supernus Pharmaceuticals SUPN Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's return on equity?
- Supernus Pharmaceuticals (SUPN) reported return on equity of -2.8% in Q1 2026.
- How has Supernus Pharmaceuticals's return on equity changed year-over-year?
- Supernus Pharmaceuticals's return on equity decreased by 143.6% year-over-year, from 6.3% to -2.8%.
- What is the long-term trend for Supernus Pharmaceuticals's return on equity?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's return on equity has grown at a -28.0% compound annual growth rate (CAGR), from 18.9% to -3.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.